Oracle Runs

Will the results be positive?

Trial NCT05743270 is withdrawn with no public readout or results posted. Sponsor discontinued RP2/RP3 dev in SCCHN (Dec 2023) to prioritize other programs, following negative CERPASS Ph2 readout in CSCC; no efficacy data or framing specific to this trial. Insufficient evidence of positive/negative readout.

Will the results be positive?

Trial (NCT05743270) is listed as withdrawn on ClinicalTrials.gov and other databases. Replimune discontinued RP2/3 development in SCCHN in Dec 2023 after a different trial (CERPASS, RP1 in cSCC) missed its endpoint, to prioritize other assets and fully discontinue RP3. No public efficacy readout, topline results, or positive/negative framing specific to this exact Phase 2 trial was located. Status is pre-results; no outcome data available.

Will the results be positive?

ClinicalTrials.gov lists this study as withdrawn but without posted results, so there is no clear public trial-specific basis yet to call the readout positive or negative.

Will the results be positive?

No clear public efficacy readout was found for this exact Phase 2 trial. The cited record shows the study is withdrawn; the ASCO item is only a trial-in-progress design poster; and Replimune’s 10-K says RP3 was deprioritized, not that this SCCHN trial read out positive or negative.

Will the results be positive?

No trial-specific efficacy readout was found. ClinicalTrials.gov lists NCT05743270 as withdrawn, and Replimune later said RP2/3 development in SCCHN was being discontinued and RP3 development stopped. That supports absence of a public positive/negative Phase 2 readout for this exact trial.